Discover Q3 2025 earnings insights from CV Sciences, Inc. See how cost control, new products, and advocacy efforts drive growth amid regulatory change.
When added to optimized oral anti-lipid therapy, a PCSK9 blocker provided an additional 25% risk reduction in a first ...
MedPage Today on MSN
Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...
It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.
Yahoo Sports TVyahoosports.tv is here! Watch live shows and highlights 24/7. Yahoo Sports DailyJason Fitz & Caroline Fenton bring you the top sports news to start your day. Yahoo Fantasy ...
Areas near the coast are likely to get 2 or more inches of rain while inland valleys receive 3 to 4 inches.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback